Pharma
Commented by Fabian Lorenz on February 10th, 2026 | 07:00 CET
Rheinmetall, Bayer, Avrupa Minerals: Stocks for Europe's independence in defense, pharmaceuticals, and raw materials!
Europe is working feverishly to achieve independence. This applies, among other things, to defense, raw materials, and medicines. Investors can profit from these three stocks. Avrupa Minerals is developing raw material projects in Finland, Portugal, and other countries, skillfully diversifying to reduce risks. The stock is still largely unknown, but this is likely to change soon. Rheinmetall is a basic investment, although there was a noticeable drop in its share price last week. Are expectations too high? At the beginning of 2025, there were hardly any expectations for Bayer. This made the comeback of the company and its stock all the more spectacular. Recently, positive study results have once again caused excitement. The next blockbuster is in the pipeline.
Read
Commented by Armin Schulz on February 6th, 2026 | 07:00 CET
Almonty Industries Surges, Novo Nordisk and PayPal Correct: Where Are the Entry Points?
The stock market is increasingly divided. While mining stocks are benefiting from geopolitical upheavals and the strategic race for raw materials, established market heavyweights are being punished at the slightest disappointment. This shift reflects the growing limits of globalization. Today, resilience beats efficiency. Three very different companies illustrate this new environment: tungsten producer Almonty Industries, pharmaceutical giant Novo Nordisk, and payment service provider PayPal. We analyze the current situation.
Read
Commented by Armin Schulz on February 5th, 2026 | 09:30 CET
SAP in free fall! RE Royalties soaring - and how is Bayer's turnaround progressing?
The stock market is divided. Established names are tumbling, while niche players are booming. Software giant SAP is facing a crisis of confidence after disappointing forecasts. Its share price slump highlights how unforgiving markets are toward stagnating growth. At the same time, a smaller name is attracting attention. RE Royalties is benefiting from the exploding demand for electricity from AI with its renewable energy business model and is attracting investors with generous dividends. In between, pharmaceutical giant Bayer is battling the legacy issues of a prolonged downturn and showing that its turnaround is increasingly gaining traction. We take a closer look at the current situation.
Read
Commented by Fabian Lorenz on February 4th, 2026 | 08:50 CET
Yesterday +10%! Top news drives shares of Evotec, Novo Nordisk, and CHAR Technologies!
Evotec shares jumped, climbing more than 10% as analysts pushed the stock higher. Does this signal that the turnaround is finally happening, or does Deutsche Bank still have the final say? Strong news also for CHAR Technologies: the Canadian company is launching commercialization of its unique technology for producing biochar and renewable natural gas substitutes from biogenic waste materials. For the expansion, it has secured strong partners, including steel giant ArcelorMittal and the Canadian BMI Group. And what is Novo Nordisk doing? The Danish company presented positive study results for its successor to Wegovy. However, analysts are not exactly thrilled.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Nico Popp on January 30th, 2026 | 07:25 CET
The hunt for the cancer pill from BioNTech & Co.: Why Eli Lilly's billion-dollar bet is a wake-up call for Vidac Pharma
It is one of the oldest rules in the biotech sector: when the big pharmaceutical companies can no longer grow on their own, they open their coffers. The latest billion-dollar deal between US giant Eli Lilly and Dresden-based startup Seamless Therapeutics is more than just a headline – it is a wake-up call for the entire industry. Eli Lilly, now one of the most valuable companies in the world, is desperately seeking innovations to secure its pipeline beyond its booming weight-loss injections. This hunger for new mechanisms of action inevitably focuses attention on small, specialized companies researching revolutionary approaches. In this environment, Vidac Pharma is becoming the focus of strategic investors. The Company is working on an approach that is as elegant as it is radical: it aims to starve cancer rather than poison it by manipulating its metabolism. While Eli Lilly and BioNTech are spreading their billions across a wide range of areas, Vidac is delivering precisely the kind of specialized "deep science" that is often lacking in the pipelines of the big players.
Read
Commented by André Will-Laudien on January 26th, 2026 | 07:30 CET
Biotech and life sciences are booming, and now Mercosur is joining the fray! Bayer, MustGrow, Novo Nordisk, and BioNxt Solutions in focus
The 2026 stock market year has a few surprises in store for investors. In addition to a quick resolution to the Greenland dispute, the Mercosur trade agreement with several South American countries is also moving forward. This agreement is particularly significant for the agricultural industry. This global sector of human supply is increasingly characterized by regulatory pressure, which is effectively ending the use of many synthetic pesticides and fertilizers. This development is forcing established agricultural companies to integrate effective biological alternatives into their portfolios faster than planned. In this environment, MustGrow Biologics is positioning itself as a strategic technology provider whose active ingredients have already been validated by leading market players. An expanded sector view also covers the life sciences industry with the protagonists Bayer, Novo Nordisk, and BioNxt. Up 50% in just a few weeks, here they are!
Read
Commented by André Will-Laudien on January 19th, 2026 | 07:20 CET
Black Monday: Despite Greenland disputes, tariffs, and Mercosur, biotech is on the rise! Bayer, Vidac Pharma, BioNTech, and Novo Nordisk in focus
The stock market has had a very volatile start to 2026. Now, due to the unresolved Greenland issue, punitive tariffs are even being reintroduced for European countries that wish to stick with the Danish administration. Questions of international law did not impact the stock market in any of the conflicts of 2025. What usually receives a lot of attention, however, are shrinking margins caused by artificial tariffs. Just as the EU had been patting itself on the back over the Mercosur agreement, the next Trump-style threat is looming. The biotech sector is advancing steadily and with considerable momentum. Can the life sciences leaders outperform the DAX?
Read
Commented by Fabian Lorenz on January 16th, 2026 | 07:05 CET
First Majestic reports, but the stock fails to benefit! Bayer continues to rise! Silver Viper takes off!
The upward trend in silver remains fully intact, and clear triple-digit price targets are circulating through the market. Yesterday, core holding First Majestic Silver reported on the fourth quarter and full year 2025. However, the stock failed to benefit from the news. Investors may find better opportunities in 2026 with Silver Viper shares. The silver explorer is undergoing a transformation and now holds three projects in Mexico. The most recent capital increase was met with strong demand, and drilling programs and results are expected in the current year. Looking at the share price chart of Bayer, one might think that the Leverkusen-based company had struck silver. The share price rose sharply in the first few days of the new year. However, analysts believe the upside potential has largely been exhausted.
Read
Commented by Nico Popp on January 14th, 2026 | 07:20 CET
Targeting cancer metabolism: Why Bayer and Pfizer are restructuring - and why Vidac Pharma is filling a scientific gap
The investment year 2026 marks a decisive turning point for the global biotechnology and pharmaceutical sector. After a period of macroeconomic uncertainty, we are witnessing a renaissance in the life sciences, driven by two fundamental forces: the urgent need for big pharma players to replace their expiring patents with innovation, and the scientific breakthrough of novel mechanisms of action in agile biotech small caps. While industry giants such as Pfizer and Bayer are attempting to steer their cumbersome tankers onto a new course through massive restructuring, the as-yet little-noticed biotech company Vidac Pharma is delivering the technological innovation the market is looking for. With an approach that directly addresses cancer metabolism and reverses the "Warburg effect," which has been known for almost a century, Vidac is positioning itself as a disruptive force in oncology and dermatology. For investors, this constellation offers a rare opportunity: to observe the stability of the giants while betting on the explosive potential of a technological innovator that analysts say is massively undervalued.
Read